These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 29584848)

  • 21. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
    Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety?].
    Jacomet C; Lebeller C; Schiestel T; Grandvuillemin A; Davani S; Valnet-Rabier MB
    Therapie; 2022; 77(6):635-647. PubMed ID: 35643745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.
    Van Slyke L; Scott M
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760846. PubMed ID: 29534653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G; Sauermilch D; Gandhi M; Starks TJ
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
    Lehman DA; Baeten JM; McCoy CO; Weis JF; Peterson D; Mbara G; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Frenkel L; Ndase P; Mugo NR; Celum C; Overbaugh J; Matsen FA;
    J Infect Dis; 2015 Apr; 211(8):1211-8. PubMed ID: 25587020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
    Chen X; Li J; Kou L; Xie X; Wei D; Li Y
    Rev Med Virol; 2023 Jul; 33(4):e2460. PubMed ID: 37198721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximizing the Benefits of HIV Preexposure Prophylaxis.
    Buchbinder SP
    Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
    Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
    JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.
    Mugwanya KK; John-Stewart G; Baeten J
    Expert Opin Drug Saf; 2017 Jul; 16(7):867-871. PubMed ID: 28571500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.